Abstract
A series of 5-aryl thiazolidine-2,4-diones containing 4-phenoxyphenyl side chains was designed, synthesized, and evaluated for PPAR agonist activities. One such compound 28 exhibited comparable levels of glucose correction to rosiglitazone in the db/db mouse type 2 diabetes animal model.
MeSH terms
-
Animals
-
Blood Glucose / drug effects
-
Diabetes Mellitus, Type 2 / drug therapy
-
Disease Models, Animal
-
Hypoglycemic Agents / chemical synthesis*
-
Hypoglycemic Agents / pharmacokinetics
-
Hypoglycemic Agents / pharmacology
-
Inhibitory Concentration 50
-
Mice
-
Receptors, Cytoplasmic and Nuclear / agonists*
-
Structure-Activity Relationship
-
Thiazolidinediones / chemical synthesis*
-
Thiazolidinediones / pharmacokinetics*
-
Thiazolidinediones / pharmacology
-
Transcription Factors / agonists*
Substances
-
Blood Glucose
-
Hypoglycemic Agents
-
Receptors, Cytoplasmic and Nuclear
-
Thiazolidinediones
-
Transcription Factors
-
2,4-thiazolidinedione